All News

28 February 2007

HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn’s DiseaseAntibodies

28 February 2007

EvoGenix and Vegenics announce collaborationAntibodies

28 February 2007

Vaccinex Announces Antibody Development And Commercialization Alliance In Multiple Sclerosis And OncologyAntibodies

28 February 2007

Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate CancerAntibodies

27 February 2007

Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in JapanAntibodies

24 February 2007

Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancerAntibodies

23 February 2007

Significant Phase III Results with CIMZIA(TM) in Rheumatoid ArthritisAntibodies

23 February 2007

Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) AntibodyAntibodies

23 February 2007

New phase III study confirms positive outcome of Avastin in patients with advanced lung cancerAntibodies

15 February 2007

DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platformAntibodies

15 February 2007

Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C InfectionAntibodies

15 February 2007

Viventia Biotech provides update on cancer antibody clinical development programsAntibodies

14 February 2007

Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization AgreementAntibodies

14 February 2007

Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 ProgramsAntibodies

14 February 2007

GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosusAntibodies

13 February 2007

BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-402Antibodies

8 February 2007

Johnson & Johnson Psoriasis Drug CNTO 1275 Posts Mixed Results In Phase 2 TrialAntibodies

8 February 2007

Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic LeukemiaAntibodies

7 February 2007

ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121BAntibodies

6 February 2007

UCB Licenses BioWa’s POTELLIGENT(R) Technology for use in Antibody Research and DevelopmentAntibodies

6 February 2007

Merck KGaA Seeks Approval for Erbitux for Colorectal Cancer in JapanAntibodies

6 February 2007

AstraZeneca Licenses Regeneron’s Velocimmune(R) Technology For Discovering Human Monoclonal AntibodiesAntibodies

3 February 2007

Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot PsoriasisAntibodies

2 February 2007

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26Antibodies

26 January 2007

Amgen’s Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 BillionAntibodies

26 January 2007

Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s LymphomaAntibodies

25 January 2007

First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritisAntibodies

25 January 2007

Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal AntibodyAntibodies

25 January 2007

Lucentis receives approval in the European Union – the first drug to improve vision in patients with wet AMD, a leading cause of blindnessAntibodies

24 January 2007

Medarex and Compugen Announce Therapeutic Antibody Co-Development AgreementAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

FcRn Inhibitors Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

CCR8-Targeted Antibody Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount